Interacting Drugs |
Butalbital compound and codeine vs Ibritumomab |
Security Level |
|
Mechanism |
Ibritumomab: Antiplatelet Agents may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding. |
Management |
Monitor therapy |
Butalbital compound and codeine vs Ibritumomab
Post Review about Butalbital compound and codeine vs Ibritumomab Click here to cancel reply.
Other Interactions of Butalbital compound and codeine
Other Interactions of Ibritumomab
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.